MedTrace Logo

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

NCT04096911 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-09-20

No results posted yet for this study

Summary

The investigators propose to evaluate the efficacy of the combination of Pd-1 Monoclonal Antibody and HPV Vaccine in the patients with cervical cancer who fails in or can not endure the standard treatment

Conditions

  • Uterine Cervical Neoplasms
  • Cervical Cancer
  • Cervical Neoplasms
  • Cervix Cancer

Interventions

DRUG

Sintilimab

Sintilimab 200 mg intravenously every 3 weeks

DRUG

quadrivalent HPV vaccine

The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    collaborator INDUSTRY

  • Buhai Wang

    lead OTHER

Principal Investigators

  • Buhai Wang · People's hospital of northern jiangsu

  • Yuechao Wu · People's hospital of northern jiangsu

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04096911 on ClinicalTrials.gov